Furlan M, Stucki B, Steinmann C, Jungo M, Lämmle B
Central Hematology Laboratory, Inselspital, University Hospital of Bern, Switzerland.
Thromb Haemost. 1996 Sep;76(3):377-83.
Calcium ions are known to accelerate polymerization of fibrin monomers. Each of the two carboxy terminal domains of normal fibrinogen contains one high-affinity calcium binding site that seems to be situated close to the polymerization site in the gamma-chain. Most hitherto described functionally defective fibrinogen variants showed impaired clot formation. Since the tightly bound calcium ions may influence the conformation of the polymerization site, the question arises whether the abnormal clotting of a dysfibrinogen might be due to defective calcium binding. We investigated binding of calcium to fibrinogen and the effect of calcium on the clotting properties of five heterozygous fibrinogen variants showing normal thrombin-induced fibrinopeptide release but abnormal polymerization of fibrin monomers. Each of these dysfibrinogens has one single amino acid substitution in the carboxy-terminal part of the gamma-chain: fibrinogen Claro (gamma 275 Arg-->His), Milano V (gamma 275 Arg-->Cys), Milano I (gamma 330 Asp-->Val), Bern I (gamma 337 Asn-->Lys), and Milano VII (gamma 358 Ser-->Cys). The shortest thrombin clotting time and the earliest onset of turbidity increase were observed in fibrinogen gamma 358 Ser-->Cys; both parameters were little affected by calcium concentration. In the variant gamma 337 Asn-->Lys, the thrombin time was abnormally prolonged at 0.01 mM Ca2+, but it was normalized at 1 mM calcium. In contrast, the abnormal fibrin polymerization of fibrinogen gamma 330 Asp-->Val was barely improved at increasing calcium concentrations. Both variants with the substitution of gamma 275 Arg, the residue indispensable for normal D:D interactions, showed the slowest rate of fibrin polymerization and the lowest turbidity of fibrin clots at any Ca2+ concentration used. High affinity calcium binding was found to be normal in all five fibrinogen variants studied, suggesting that their abnormal clotting was not due to defective binding of calcium. The gamma-chain in the fragment D1 derived from the variant gamma 337 Asn-->Lys was further degraded by plasmin in the presence and in the absence of calcium, whereas fragments D1 from the other four gamma-chain variants as well as from normal fibrinogen were protected against plasmic degradation in the presence of 1 mM Ca2+.
已知钙离子可加速纤维蛋白单体的聚合。正常纤维蛋白原的两个羧基末端结构域各包含一个高亲和力钙结合位点,该位点似乎位于γ链的聚合位点附近。迄今描述的大多数功能缺陷型纤维蛋白原变体都表现出凝血形成受损。由于紧密结合的钙离子可能会影响聚合位点的构象,因此出现了一个问题,即异常纤维蛋白原的异常凝血是否可能归因于钙结合缺陷。我们研究了钙与纤维蛋白原的结合以及钙对五种杂合纤维蛋白原变体凝血特性的影响,这些变体显示凝血酶诱导的纤维蛋白肽释放正常,但纤维蛋白单体聚合异常。这些异常纤维蛋白原中的每一种在γ链的羧基末端部分都有一个单一氨基酸取代:纤维蛋白原Claro(γ275 Arg→His)、米兰诺V(γ275 Arg→Cys)、米兰诺I(γ330 Asp→Val)、伯尔尼I(γ337 Asn→Lys)和米兰诺VII(γ358 Ser→Cys)。在纤维蛋白原γ358 Ser→Cys中观察到最短的凝血酶凝血时间和最早的浊度增加;这两个参数受钙浓度的影响很小。在变体γ337 Asn→Lys中,凝血酶时间在0.01 mM Ca2+时异常延长,但在1 mM钙时恢复正常。相反,在增加钙浓度时,纤维蛋白原γ330 Asp→Val的异常纤维蛋白聚合几乎没有改善。在使用的任何Ca2+浓度下,γ275 Arg取代的两个变体(正常D:D相互作用所必需的残基)都显示出最慢的纤维蛋白聚合速率和最低的纤维蛋白凝块浊度。在研究的所有五种纤维蛋白原变体中发现高亲和力钙结合正常,这表明它们的异常凝血不是由于钙结合缺陷。来自变体γ337 Asn→Lys的片段D1中的γ链在有钙和无钙的情况下都被纤溶酶进一步降解,而来自其他四种γ链变体以及正常纤维蛋白原的片段D1在1 mM Ca2+存在下可防止血浆降解。